Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Increases By 59.4%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 878,500 shares, a growth of 59.4% from the February 28th total of 551,300 shares. Approximately 13.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,770,000 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Ratings Changes

Several brokerages have commented on TNXP. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating for the company. Noble Financial reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth approximately $40,000. Two Sigma Investments LP bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $66,000. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at approximately $72,000. Northern Trust Corp bought a new stake in Tonix Pharmaceuticals in the fourth quarter worth $162,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Trading Down 24.4 %

NASDAQ:TNXP opened at $20.17 on Friday. The firm has a market capitalization of $37.70 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a fifty day moving average of $18.79 and a 200 day moving average of $20.13. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a 52 week low of $6.76 and a 52 week high of $672.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The company had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, research analysts predict that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.